Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Emergent BioSolutions Inc EBS

Healthcare Biotechnology
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial Products segment include NARCAN (naloxone HCl). MCM Products segment consists of its Anthrax - MCM, Smallpox - MCM and Other Products. Services segment consisting of its Bioservices offerings. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Its portfolio of Bioservices consists of three but interrelated service pillars, such as development services (process and analytical development) and drug substance manufacturing.


NYSE:EBS - Post by User

Emergent BioSolutions Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(4)
•••
Post by AviseAnalyticson Jun 27, 2022 8:05am
194 Views
Post# 34783975

HERE’S WHY EMERGENT BIOSOLUTIONS IS WORTH INVESTING!

HERE’S WHY EMERGENT BIOSOLUTIONS IS WORTH INVESTING!
$EBS
 
Emergent BioSolutions, Inc. (NYSE:EBS), a life sciences company is developing a portfolio of vaccines and therapeutics for urgent health threats, announced the acceptance of a Biologics License Application (BLA) for AV7909 (Anthrax Vaccine Adsorbed, Adjuvanted) by the U.S. Food and Drug Administration (FDA). 
 
Here's what you need to know before investing in the Company!

https://www.aviseanalytics.com/heres-why-emergent-biosolutions-is-worth-investing/
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities